{Reference Type}: Journal Article
{Title}: Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays.
{Author}: Hyams DM;Bareket-Samish A;Rocha JEB;Diaz-Botero S;Franco S;Gagliato D;Gomez HL;Korbenfeld E;Krygier G;Mattar A;De Pierro AN;Borrego MR;Villarreal C;
{Journal}: J Surg Oncol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 24
{Factor}: 2.885
{DOI}: 10.1002/jso.27692
{Abstract}: Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.